Related Experiment Videos
The use of thalidomide in chronic refractory graft versus host disease
M H van de Poel1, P C Pasman, H C Schouten
1Department of Internal Medicine, Academic Hospital Maastricht, Postbus 5800, 6202 AZ Maastricht, The Netherlands.
Insights
Thalidomide shows promise for treating chronic graft-versus-host disease (GvHD) refractory to standard treatments like prednisone and cyclosporine A. Early use of thalidomide may improve outcomes in GvHD patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Chronic graft-versus-host disease (GvHD) is a significant complication following allogeneic bone marrow transplantation.
- Standard treatments, including prednisone and cyclosporine A, have limitations in efficacy for chronic GvHD.
- Investigating alternative therapeutic options is crucial for managing refractory cases.
Purpose of the Study:
- To evaluate the therapeutic value of thalidomide in patients with chronic GvHD resistant to prednisone and cyclosporine A.
- To assess the efficacy and safety profile of thalidomide in this patient population.
Main Methods:
- A retrospective analysis of 12 patients with chronic GvHD refractory to standard therapy was conducted.
- Thalidomide was administered to these patients, and outcomes were documented since 1991.
- Case histories were used to illustrate treatment responses and adverse events.
Main Results:
- Four patients achieved complete remission of chronic GvHD with thalidomide treatment.
- Five patients experienced a partial response to thalidomide.
- One patient discontinued thalidomide due to polyneuropathy; other side effects were not serious.
Conclusions:
- Thalidomide is a viable treatment option for chronic GvHD that is refractory to prednisone and cyclosporine A.
- Earlier administration of thalidomide in the GvHD course warrants further investigation.
- The findings suggest thalidomide could be a valuable addition to the GvHD treatment armamentarium.
Background:
Chronic graft versus host disease (GvHD) is a serious complication of allogenic bone marrow transplantation. As prednisone and ciclosporine A are not always effective in its treatment, we investigated the value of thalidomide.
Methods:
We describe the results of thalidomide in 12 patients with chronic prednison/ciclosporin A refractory GvHD seen in our clinic since 1991. A case history is given as illustration.
Results:
Four patients had a complete remission of chronic GvHD on thalidomide; five patients showed a partial response. Of these five patients, three died eventually of respectively ongoing GvHD, pneumonia and recurrent leukemia. There were no serious side effects, except for one patient who had to stop thalidomide because of polyneuropathy.
Conclusions:
It is worthwhile to give thalidomide in prednison/ciclosporin A refractory chronic GvHD. Probably thalidomide should be given earlier in the course of GvHD, this needs further study.